(Q38058884)

27 August 2017

title

Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer (English)

1 reference

27 August 2017

1 reference

1 reference

Joan N Kyula

1

1 reference

27 August 2017

Victoria Roulstone

2

1 reference

27 August 2017

Eleni M Karapanagiotou

3

1 reference

27 August 2017

Alan A Melcher

4

1 reference

27 August 2017

Kevin J Harrington

5

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 December 2012

1 reference

Expert Opinion on Biological Therapy

27 August 2017

published in

1 reference

27 August 2017

volume

12

1 reference

27 August 2017

issue

12

1 reference

27 August 2017

page(s)

1669-1678

1 reference

Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Oropharyngeal carcinoma related to human papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Prevalence of Reovirus‐Specific Antibodies in Young Children in Nashville, Tennessee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

A strategy for genetic modification of the spike-encoding segment of human reovirus T3D for reovirus targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

The preferential cytotoxicity of reovirus for certain transformed cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Reovirus therapy of tumors with activated Ras pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Biological significance of c-erbB family oncogenes in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Genetically targeted cancer therapy: tumor destruction by PKR activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Proteolytic disassembly is a critical determinant for reovirus oncolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Reovirus: viral therapy for cancer 'as nature intended'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.745507

10.1517/14712598.2012.745507

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference